Search Patents
  • Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use
    Publication number: 20080108620
    Abstract: The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.
    Type: Application
    Filed: July 19, 2005
    Publication date: May 8, 2008
    Applicant: MERCK & CO., INC.
    Inventors: Linda Brockunier, Jian Guo, Rui Liang, Emma R. Parmee, Subharekha Raghavan, George Scott Tria, Yusheng Xiong
  • SILICON DIOXIDE NANOPARTICLES AND THE USE THEREOF FOR VACCINATION
    Publication number: 20180071386
    Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.
    Type: Application
    Filed: October 6, 2017
    Publication date: March 15, 2018
    Applicant: Merck Patent GmbH
    Inventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
  • Anisotropic compounds having Nematic phase and liquid crystal mixtures
    Patent number: 5310501
    Abstract: Anisotropic compounds having a nematic phase have the formula ##STR1## wherein R.sup.1, R.sup.2, A, Z, X and n are described in the specification.Compounds having the defined lateral substituents on the rings have a reduced tendency to form smectic phases as compared with the compounds not having such lateral substituents.
    Type: Grant
    Filed: January 25, 1993
    Date of Patent: May 10, 1994
    Assignee: Merck Patent GmbH
    Inventors: Tuong Huynh-Ba, Maged A. Osman
  • Tricyclic heterocycle compounds useful as HIV integrase inhibitors
    Patent number: 10934312
    Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein A, X, Y, Z, R1, R7A, R7B and R8 are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: March 2, 2021
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Thomas H. Graham, Tao Yu, Sherman T. Waddell, John A. McCauley
  • Estrogen receptor
    Patent number: 6222015
    Abstract: This invention relates to a novel estrogen receptor and to the polynucleotide sequences encoding this receptor. This invention also relates to methods for identifying ligands which bind to this receptor, to the ligands so identified, and to pharmaceutical compositions comprising such ligands. This invention also relates to pharmaceutical compositions useful for treating or preventing estrogen receptor mediated diseases or conditions, such as abnormal bone resorption, cardiovascular diseases, cancer, or central nervous system disorders.
    Type: Grant
    Filed: August 25, 1998
    Date of Patent: April 24, 2001
    Assignee: Merck & Co., Inc.
    Inventor: Hilary Wilkinson
  • LIQUID CRYSTALLINE MEDIUM
    Publication number: 20100176341
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds having negative dielectric anisotropy, which contains at least one compound of the formula I and at least one compound of the formula II in which R1, R2, R3, R4, ring A, Z1, Z2 and m are as defined in Claim 1, and to the use thereof for an active-matrix display based on the ECB, VA, PS-VA, FFS, PALC or IPS effect.
    Type: Application
    Filed: May 21, 2008
    Publication date: July 15, 2010
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Norihiko Tanaka, Makoto Murakami, Shinji Nakajima
  • MurD protein and gene of Staphylococcus aureus
    Patent number: 6534284
    Abstract: This invention provides the murD gene of Staphylococcus aureas. Purified and isolated MurD recombinant proteins are also provided. Nucleic acid sequences which encode functionally active MurD proteins are described. Assays for the identification of modulators of the expression of murD and inhibitors of the activity of MurD, are also provided.
    Type: Grant
    Filed: May 3, 2000
    Date of Patent: March 18, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mohammed El-Sherbeini, Kenny Kin Wong, Wayne M. Geissler
  • COMPOUNDS FOR ELECTRONIC DEVICES
    Publication number: 20140231715
    Abstract: The present invention relates to a compound of the formula (I), to the use of this compound in an electronic device, and to an electronic device comprising one or more compounds of the formula (I). The invention furthermore relates to the preparation of the compound of the formula (I) and to a formulation comprising one or more compounds of the formula (I).
    Type: Application
    Filed: March 23, 2012
    Publication date: August 21, 2014
    Applicant: Merck Patent GmbH Patents & Scientific Information
    Inventors: Philipp Stoessel, Arne Buesing, Frank Voges, Christof Pflumm, Amir Hossain Parham, Thomas Eberle, Teresa Mujica-Fernaud
  • Imidazolidyl macrolides having immunosuppressive activity
    Patent number: 5344925
    Abstract: Imidazolidyl macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.
    Type: Grant
    Filed: September 20, 1993
    Date of Patent: September 6, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
  • Optical switch element comprising a liquid-crystalline medium
    Patent number: 9416314
    Abstract: The present invention relates to an optical switch element, comprising a liquid-crystalline medium for the temperature-dependent regulation of radiant energy flow. The invention furthermore relates to the use of the optical switch element for the regulation of radiant energy flow between interior spaces and the environment and for the regulation of the temperature of interior spaces. The invention furthermore relates to a liquid-crystalline medium, characterized in that it comprises 5-95% of a compound of the formula (I), in particular for use in the optical switch elements according to the invention.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: August 16, 2016
    Assignee: Merck Patent GmbH
    Inventor: Michael Junge
  • Chromatography column
    Patent number: 4280905
    Abstract: A chromatography column adapted for high pressure chromatography is characterized by a tubular membrane separating a glass tube from the pressurized area between the glass tube and a pressure tube adapted to receive a pressurizing fluid. Changing of the glass tube is facilitated by annular seals at each end of the glass tube against which an adjustable threaded plug, fitted in one of a pair of screw caps fitted on each end of the pressure tube, exerts sealing pressure.
    Type: Grant
    Filed: July 29, 1980
    Date of Patent: July 28, 1981
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Werner Gunkel, Friedhelm Eisenbeiss
  • TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS
    Publication number: 20240043402
    Abstract: The present disclosure is directed to tetrahydroquinazoline derivatives of Formula (I) and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naive cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
    Type: Application
    Filed: December 6, 2021
    Publication date: February 8, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Antonella Converso, David N. Hunter, Abdellatif El Marrouni, Anthony J. Roecker, Anthony W. Shaw, William D. Shipe, Cheng Wang, Deping Wang, Yunlong Zhang
  • 1,1-Di(4-hydroxy-3-methoxyphenyl)-2-alkoxypropane
    Patent number: 4230893
    Abstract: 4-Hydroxy-3-methoxyphenylacetone, an intermediate for methyldopa, has been prepared from reacting two moles of guaiacol and one mole of a 2-alkoxy propanol followed by basic elimination to form the enol ether of 4-hydroxy-3-methoxy phenyl acetone. The enol ether is subsequently converted to 4-hydroxy-3-methoxy phenyl acetone upon treatment with a strong acid.
    Type: Grant
    Filed: September 13, 1979
    Date of Patent: October 28, 1980
    Assignee: Merck & Co., Inc.
    Inventor: George Gal
  • ENZYMATIC SYNTHESIS OF 4'-ETHYNYL NUCLEOSIDE ANALOGS
    Publication number: 20220228184
    Abstract: The present invention relates to an enzymatic synthesis of 4?-ethynyl-2?-deoxy nucleosides and analogs thereof, for example EFdA, that eliminates the use of protecting groups on the intermediates, improves the stereoselectivity of glycosylation and reduces the number of process steps needed to make said compounds. It also relates to the novel intermediates employed in the process.
    Type: Application
    Filed: July 2, 2019
    Publication date: July 21, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mark A. Huffman, Anna Fryszkowska, Joshua N. Kolev, Paul N. Devine, Kevin R. Campos, Matthew Truppo, Christopher C. Nawrat
  • SYSTEM AND METHOD
    Publication number: 20220202566
    Abstract: The present invention generally relates to a system for two-photon or multi-photon irradiating an artificial lens, preferably an intraocular lens preferably arranged within an eye of a patient and a method for locally adjusting a polarizability and/or a refractive index of an artificial lens preferably an intraocular lens preferably arranged within an eye of a patient. The method relates in particular to fabrication of optical profiles by adjusting polarizability through two- or multi-photon processes in a non-destructive manner.
    Type: Application
    Filed: April 24, 2020
    Publication date: June 30, 2022
    Applicant: Merck Patent GmbH
    Inventors: Martin SCHRAUB, Lars DOBELMANN-MARA, Simon HELMSTETTER, David MOORE, Stefan RIEDMUELLER, Harald GUENTHER
  • CYCLOHEXADIENE FULLERENE DERIVATIVES
    Publication number: 20150069304
    Abstract: The invention relates to novel fullerene derivatives, to methods for their preparation and educts or intermediates used therein, to mixtures and formulations containing them, to the use of the fullerene derivatives, mixtures and formulations as organic semiconductors in, or for the preparation of, organic electronic (OE) devices, especially organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising, or being prepared from, these fullerene derivatives, mixtures or formulations.
    Type: Application
    Filed: September 11, 2014
    Publication date: March 12, 2015
    Applicants: Nano-C, Inc., MERCK PATENT GMBH
    Inventors: Nicolas BLOUIN, Stephane BERNY, Edward A. JACKSON, Henning RICHTER, Feng HE
  • Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1B (PTP-1B)
    Patent number: 6365592
    Abstract: The invention encompasses compounds represented by formula I: as well as compositions and methods of treatment. The compounds are inhibitors of the PTP-1B enzyme.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: April 2, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yves Leblanc, Claude Dufresne, Patrick Roy, Zhaoyin Wang
  • .beta.-Adrenergic 2-[4-(3-amino-2-hydroxypropoxy)phenyl]imidazoles
    Patent number: 4567276
    Abstract: Novel substituted imidazoles and methods for their preparation are disclosed. These imidazoles, and their salts, exhibit pharmacological activity which includes antihypertensive activity and .beta.-adrenergic blocking activity.
    Type: Grant
    Filed: June 13, 1983
    Date of Patent: January 28, 1986
    Assignee: Merck & Co., Inc.
    Inventor: John J. Baldwin
  • Anti-PD-L1 antibodies and uses thereof
    Patent number: 9624298
    Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: April 18, 2017
    Assignee: Merck Patent GmbH
    Inventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
  • Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
    Patent number: 5334719
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: June 17, 1992
    Date of Patent: August 2, 1994
    Assignee: Merck Frosst Canada, Inc.
    Inventor: Richard Frenette
Narrow Results

Filter by US Classification